STAT is a family of cytoplasmic protein that regulates many aspects of growth, survival and differentiation in cells. The Janus kinase family of transcription factors is activated, and dysregulation of this pathway, which promotes angiogenesis, tumor survival, and immunosuppression, is frequently seen in primary tumors. Gene knockout studies have shown that STAT proteins are important for immune system development and operation, immune tolerance maintenance, and tumor surveillance.Initially, STAT proteins were thought to be dormant cytoplasmic transcription factors that needed to be phosphorylated in order to be retained in the nucleus. While awaiting an activation signal, the unphosphorylated STAT proteins move back and forth between the cytosol and the nucleus. The transcription of cytokine-inducible genes is activated once the activated transcription factor enters the nucleus and binds to the consensus DNA-recognition motif known as gamma-activated sites (GAS) in the promoter region.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V87055 | (E/Z)-OSM-SMI-10B | 2502294-55-3 | (E/Z)-OSM-SMI-10B is a derivative of OSM-SMI-10. |
|
V69139 | (R)-Lisofylline ((R)-Lisophylline) | 100324-81-0 | (R)-Lisofylline ((R)-Lisophylline) is the (R)-enantiomer of the Pentoxifylline metabolite and has anti-inflammatory activities. |
|
V51515 | (R,R)-VVD-118313 | 2875046-31-2 | (R,R)-VVD-118313 is the seven bodies of VVD-118313. |
|
V117718 | (trans)-STAT6 modulator-5 | (trans)-STAT6 regulator-5 (compound 95) is a STAT6 protein regulator that inhibits the STAT6 signaling pathway. | |
|
V122282 | (trans)-STAT6-IN-13 | (trans)-STAT6-IN-13 is a STAT6 inhibitor with an IC50 value ≤300 nM. | |
|
V102604 | 15(R)-Lipoxin A4 | 171030-11-8 | 15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and lipid-derived lipoxin-type resolution mediator (SPM) that promotes the resolution of inflammation and regulates immune cell function. |
|
V124569 | 2-Chloro-5-(trifluoromethyl)pyrimidine | 69034-12-4 | 2-Chloro-5-(trifluoromethyl)pyrimidine is a chemical intermediate. |
|
V85008 | 5-FAM-GpYLPQTV-NH2 | 769166-98-5 | |
|
V87041 | 5-FAM-GpYLPQTV-NH2 TFA | 5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide with STAT3 inhibitory activity. | |
|
V85002 | Ac-GpYLPQTV-NH2 | 1349616-70-1 | |
|
V106122 | Ac-GpYLPQTV-NH2 acetate | Ac-GpYLPQTV-NH2 acetate is a STAT3 inhibitor with IC50 of 0.33 μM. | |
|
V128440 | AKR1B1/STAT3/SLC7A11-regulator-1 | 2632263-80-8 | AKR1B1/STAT3/SLC7A11-regulator-1 is an AKR1B1/STAT3/SLC7A11 regulator that reverses doxorubicin resistance in MCF-7/ADR cells by enhancing ferroptosis activity. |
|
V69136 | Angoline | 21080-31-9 | Angoline is a potent and specific inhibitor of the IL6/STAT3 signaling pathway with IC50 of 11.56 μM. |
|
V69143 | Angoline hydrochloride | 1071676-04-4 | Angoline HCl is a potent and specific inhibitor of the IL6/STAT3 signaling pathway with IC50 of 11.56 μM. |
|
V101159 | Anti-inflammatory agent 92 | 1609387-77-0 | Anti-inflammatory agent 92 (compound LD4) is a porphyrin derivative. |
|
V104473 | Anticancer agent 259 | Anticancer agent 259 (compound 3g) is a telmisartan-based cell death regulator that interferes with the STAT5 signaling pathway and enhances the sensitivity of resistant cells to imatinib, with a SC50 of 1.5 μM. | |
|
V129179 | Antitumor agent-195 | Antitumor agent-195 is a dual-target drug targeting STAT3 and NQO1. | |
|
V69156 | Antitumor agent-73 | 2812356-72-0 | Antitumor agent-73 is an analogue of Diosgenin, which can inhibit the STAT3 signaling pathway and exogenously activate Pdia3/ERp57. |
|
V69144 | APT STAT3 | 1345420-96-3 | APT STAT3 is a specific STAT3-binding peptide. |
|
V2981 | AS1517499 | 919486-40-1 | AS1517499 is a potent STAT6 inhibitor with IC50of 21 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
